JMS CO., LTD.

1

Company Code No: 7702

http://www.jms.cc/

The assessment figures described on this report are based on available information

at this moment, including uncertain data. Actual results may be different from the figures.

Financial Statements for FYE Mar. 2012

From Apr. 1, 2011 to Mar. 31, 2012

Summary of consolidated results

2

Highlights in Business Results

- Labor costs and material costs increased, as well as the influence from the decreased Sales

affected by the exchange rate.

- Temporal expenses for the personnel-system revision.

- Investment gain by equity method posted, but tax expense increased.

Dividend：：：：Annual dividend of JPY 8 per share is planned (Interim dividend: JPY 4 per share)

Operating Income: JPY 1.05 billion (38.4%), Ordinary Income: JPY 1.38 billion (24.6%),

Net Income: JPY 0.94 billion (27.0%)

[Japan][Japan]

- Sales of infusion and transfusion products, which contribute enhancing safety and streamlining

in medical care, increased steadily.

- Sales of dialysis products including a dialysis machine with new functions increased steadily.

[Overseas][Overseas]

- Sales of AV fistula needle (needle for Hemodialysis), which has a high share in North America

and EU, expanded steadily.

- Sales amount was reduced due to the influence of exchange rate.

Sales: JPY 46.83 billion 2.7%

Increased in sales and decreased in profits for FYE Mar. 2012

（%: compared with previous year )

Sa

les

Pro

fit

3

Consolidated Business Result

---

88.5%

25.6%

5.2%

0.7%

Compared

with the

forecast

JPY11.59

500

1,100

1,000

46,500

Last announced

forecast

FYE Mar. 2012

(27.0%)9421,291Net Income

Year

-over-

year

(%)

Results

2.7%46,83645,587Sales

JPY21.84

1,382

1,052

---

(24.6%)

(38.4%)

JPY29.91Net Income per share

1,707Operating Income

1,833Ordinary Income

Results

FYE Mar. 2011

(unit: JPY Million)Increased in sales, decreased in profits

4

Japan

(JMSJ)

Southeast Asia

(JMSS)

China

(JMSD)Germany

(BIONIC)

America

(JMSNA)

38,827

12,269

2,919 2,7992,175

34,406

5,437

913 2,175

FYE Mar. 2011 FYE Mar. 2012

37,760

11,821

5,4092,631

780

2,925

2,925

2,223

2,223

33,249

Korea

(JMSK)

1,105999

35,000

30,000

5,000

40,000

0

10,000

15,000

2,798

Sales by Segment (Company)

(unit: JPY Million)

Sales incl. internal transactionSales incl. internal transaction

Sales for third partySales for third party

5

600

104157

222 219

1,007

242 237 233

166

112102

1,000

800

200

1,200

0

400

600

FYE Mar. 2012FYE Mar. 2011(unit: JPY Million)

Japan

(JMSJ)

Southeast Asia

(JMSS)

China

(JMSD)Germany

(BIONIC)

America

(JMSNA)

Korea

(JMSK)

Profit by Segment (Company)

6

In addition to favorable sales of dialysis machine

with new functions, sales of Infusion set /

Extension tube with “PLANECTA”, a needleless

access port, increased steadily.

Southeast Asia

(JMSS)

China

(JMSD)

Sales of Blood tubing set for Japanese market and

AV Fistula needle for North American market

increased steadily.

Sales of Infusion set for Japanese market

increased. Sales of Dialyzer and Blood tubing set

were expanded in Chinese market.

Japan

(JMSJ)

2.8%

(40.4%)

（%: year-over-year）

3.8%

(57.2%)

10.9%

(33.6%)

Dialysis machine

“GC-110N”GC-110N is a dialysis machine

for safe and efficient therapy,

which contributes to promotion

of operation streamlining and

prevention of incorrect

operation by its automated

function for complicated

processes such as priming,

blood pulling/returning.

Summary by Segment (Company)

Million yen

Million yen

600Ordinary Income

38,827Sales

Million yen

Million yen

104Ordinary Income

12,269Sales

Million yen

Million yen

157Ordinary Income

2,919Sales

Infusion set with a

needleless access port,

“PLANECTA”

Infusion set is used for drug administration to a

human body. “PLANECTA” is a needleless access

port, allowing connections without a needle, which

offers minimized infection risk to patients and

medical staff by reducing the risk of contamination

coming from blood or solution, and preventing

needle-stick accidents.

7

While sales of AV Fistula needle for German market

increased steadily, the total sales were decreased due to

decreased sales of Blood bag for East Europe and the

effect of JPY currency conversion.

America

(JMSNA)

Korea

(JMSK)

While sales of AV Fistula needle increased along with

business expansion by a major customer, the total sales

were decreased due to the effect of JPY currency

conversion.

Germany

(BIONIC)

(4.3%)

(4.5%)

(2.2%)

32.3%

10.5%

9.9%

Million yen

Million yen

222Ordinary Income

2,798Sales

Million yen

Million yen

219Ordinary Income

2,175Sales

Million yen

Million yen

112Ordinary Income

1,105Sales

Summary by Segment (Company)

Artificial kidney

(Dialyzer)

This medical product is used for removing

extra fluid and waste products from a

patient during a dialysis therapy, via its

hollow-fiber membrane.

“SysLoc”, AV Fistula needle combined

with a safety function for preventing

needle-stick accidents

AV Fistula needle is for pulling blood from

a patient during a dialysis therapy.

“SysLoc” has a safety function for

preventing medical staff from having

needle-stick accidents by guarding the

needle inside the wing after use.

1. Cannulation 2. Retracting needle 3. Locked

（%: year-over-year）

8

20,83114,821

4,2904,206

1,438

20,969 15,771

4,4234,143

1,529

5,000

10,000

15,000

20,000

25,000

輸液輸血群 透析群 一般用品群 循環器群 その他

133 3%

138 1%950 6%

(63) (1%)

90 6%

Sales by Business Segment

FYE Mar. 2011 FYE Mar. 2012

(unit: JPY Million)

DialysisInfusion and

Transfusion

General medical

supplies

Cardiovascular Others

0

9

48,000

46,000

45,000

44,000

43,000

47,000

0

49,000

42,000

46,836

45,587

JPY 47,624 Million

Up 4.5% year-over-year

（excluding effect of

exchange rate）

JPY 47,624 Million

Up 4.5% year-over-year

（excluding effect of

exchange rate）

JPY 46,836 Million

Up 2.7% year-over-year

JPY 46,836 Million

Up 2.7% year-over-year

Sales : Compared with the Previous Year

(unit: JPY Million)

Amount affected by exchange rate:

JPY 788 Million

FYE Mar. 2011 FYE Mar. 2012

10

11,687

11,519

25.3% 25.0%

7,000

8,000

9,000

10,000

11,000

12,000

13,000

23年3月期 24年3月期

0%

20%

40%

60%

SGA (0.3%)

Selling, General and Administrative Expenses

(unit: JPY Million)

(unit: JPY Million)

FYE Mar.

2011

FYE Mar.

2012

(3.8%)(56)1,4271,483R&D expense

Difference

6.6%3245,2124,887Labor cost

1.5%16711,68711,519Total

(3.7%)(124)3,2803,405Others

0.1%0458458Depreciation

cost

1.9%241,3091,284Transport cost

Y-o-Y

(%)

FYE Mar.

2012

FYE Mar.

2011

11

1,833

1,382

(134)

(208)

Minus factor Plus factor

131

(240)

Ordinary Income：：：： Compared with the Previous Year

Ordinary

Income

FYE Mar. 2011

Ordinary

Income

FYE Mar. 2012

The underlined figure doesn’t include impact of exchange rate

Impact of

exchange rate

Gross profit

decrease

Non-operating profit

increase

SGA increase

Ordinary Income decrease JPY 451 Million

(unit: JPY Million)

12

Forecast for FYE Mar. 2013

(unit: JPY Million)

With the three key words, “Medical Safety”, “Promotion of efficiency in medical care”

and “Regenerative Medicine”, JMS group is keeping its commitment to trial for

increasing profits by expanding sales of the products which contribute to medical safety

and meet the changing market demands, and promoting cost reduction in all areas.

Furthermore, with a trial for expanding its product portfolio arising from alliances, as

well as creating added value in products by its own technologies, JMS group is

promoting its sales activity.

64.5%1,550942Net profit

---JPY 35.92JPY 21.84Net profit per share

80.8%

118.6%

2.5%

Y-o-Y

(%)

2,500

2,300

48,000

FYE Mar. 2013

(Forecast)

46,836Sales

1,382Ordinary Income

1,052Operating Income

FYE Mar. 2012

(Result)

13

Uniformity of Group Accounting Policy

‐Choosing a method more suitable

for actual usage of fixed asset

‐Preparation for IFRS

Reason

Reduce by approx. JPY 850 million for

depreciation cost

（FYE Mar. 2013, consolidated basis)

Impact

Tangible fixed asset (incl. affiliates）Scope

Starting from April 1, 2012Period

From Fixed-rate to Straight-line

method

Change

～～～～ Change in depreciation method ～～～～

2,300

850

From the change in

depreciation method

1,450

1,052

Increase: 397Increase: 397

Increase: 1,247Increase: 1,247

～～～～ Operating income forecast ～～～～

FYE Mar. 2012 FYE Mar. 2013

(forecast)

FYE Mar. 2013

(forecast)

(unit: JPY Million)

*Excluding the impact from the

change in depreciation method

14

‐‐‐‐Endowing a course for kidney failure therapy at Tohoku

University < March 29, 2012>

‐‐‐‐Launching a new product “PEG ASSISTA”, an infusion system for

semisolid nutrient < April 20, 2012>

‐Signing a joint research agreement with Konkuk University

(Republic of Korea) for regenerative medicine

< March 29, 2012>

‐‐‐‐Establishing an additional building at an affiliate company for

manufacturing Prefilled syringes < November 28, 2011>

‐‐‐‐Expanding line-up of Prefilled syringe < November 28, 2011>

‐‐‐‐Launching a system for CRRT, Continuous Renal Replacement

Therapy < October 27, 2011>

Infusion system for semisolid

nutrient “PEG ASSISTA”

CRRT system

“AcuFil Auto JC-01”

Key Events

15

The Bridge to Good Health Care

JMS will continue its activities for contributing to

medical care, with our corporate philosophy “The

patient comes first”.

JMS continue to dedicate effort to creating happiness

for patients, their families and medical staff in line

with its basic principle, “offering products and

services creating an impression on customers”.

Thank you very much for your patronage and support.